Immuneering (IMRX) Liabilities and Shareholders Equity: 2020-2024
Historic Liabilities and Shareholders Equity for Immuneering (IMRX) over the last 4 years, with Sep 2024 value amounting to $68.6 million.
- Immuneering's Liabilities and Shareholders Equity fell 39.80% to $68.6 million in Q3 2024 from the same period last year, while for Sep 2024 it was $336.2 million, marking a year-over-year decrease of 28.29%. This contributed to the annual value of $102.6 million for FY2023, which is 16.17% down from last year.
- According to the latest figures from Q3 2024, Immuneering's Liabilities and Shareholders Equity is $68.6 million, which was down 11.07% from $77.1 million recorded in Q2 2024.
- In the past 5 years, Immuneering's Liabilities and Shareholders Equity registered a high of $166.7 million during Q4 2021, and its lowest value of $38.4 million during Q4 2020.
- In the last 3 years, Immuneering's Liabilities and Shareholders Equity had a median value of $113.9 million in 2023 and averaged $112.1 million.
- Per our database at Business Quant, Immuneering's Liabilities and Shareholders Equity spiked by 333.87% in 2021 and then tumbled by 39.80% in 2024.
- Quarterly analysis of 5 years shows Immuneering's Liabilities and Shareholders Equity stood at $38.4 million in 2020, then surged by 333.87% to $166.7 million in 2021, then fell by 26.60% to $122.4 million in 2022, then dropped by 16.17% to $102.6 million in 2023, then tumbled by 39.80% to $68.6 million in 2024.
- Its Liabilities and Shareholders Equity stands at $68.6 million for Q3 2024, versus $77.1 million for Q2 2024 and $88.0 million for Q1 2024.